Business Combinations and Contingent Consideration Liabilities - Additional Information (Details)
|
|
12 Months Ended |
Feb. 08, 2023 |
Dec. 31, 2025
USD ($)
|
Dec. 31, 2024
USD ($)
|
| Business Combination [Line Items] |
|
|
|
| Fair value |
|
$ 786,000
|
|
| Chronix [Member] |
|
|
|
| Business Combination [Line Items] |
|
|
|
| Fair value |
|
$ 6,700,000
|
|
| Merger Agreement [Member] | Chronix Equity [Member] |
|
|
|
| Business Combination [Line Items] |
|
|
|
| Earnout percentage on collections for sales |
10.00%
|
|
|
| Gross proceeds percentage |
5.00%
|
|
|
| Insight Genetics Inc [Member] | Discount rate [Member] | Level 3 [Member] |
|
|
|
| Business Combination [Line Items] |
|
|
|
| Business combination, contingent consideration, liability, measurement input |
|
0.123
|
|
| Insight Genetics Inc [Member] | Maximum [Member] | Discount rate [Member] | Level 3 [Member] |
|
|
|
| Business Combination [Line Items] |
|
|
|
| Business combination, contingent consideration, liability, measurement input |
|
|
0.135
|
| Insight Genetics Inc [Member] | Maximum [Member] | Management probability estimate [Member] | Level 3 [Member] |
|
|
|
| Business Combination [Line Items] |
|
|
|
| Business combination, contingent consideration, liability, measurement input |
|
0.50
|
0.50
|
| Insight Genetics Inc [Member] | Maximum [Member] | Expected term [Member] | Level 3 [Member] |
|
|
|
| Business Combination [Line Items] |
|
|
|
| Business combination, contingent consideration, liability, milestone payment |
|
1 year 10 months 24 days
|
7 years 9 months 18 days
|
| Insight Genetics Inc [Member] | Minimum [Member] | Discount rate [Member] | Level 3 [Member] |
|
|
|
| Business Combination [Line Items] |
|
|
|
| Business combination, contingent consideration, liability, measurement input |
|
|
0.132
|
| Insight Genetics Inc [Member] | Minimum [Member] | Management probability estimate [Member] | Level 3 [Member] |
|
|
|
| Business Combination [Line Items] |
|
|
|
| Business combination, contingent consideration, liability, measurement input |
|
0.25
|
0.25
|
| Insight Genetics Inc [Member] | Minimum [Member] | Expected term [Member] | Level 3 [Member] |
|
|
|
| Business Combination [Line Items] |
|
|
|
| Business combination, contingent consideration, liability, milestone payment |
|
1 year 8 months 12 days
|
1 year 8 months 12 days
|
| Insight Genetics Inc [Member] | Valuation Technique, Discounted Cash Flow [Member] |
|
|
|
| Business Combination [Line Items] |
|
|
|
| Unobservable Measurement Input, Uncertainty, Description |
|
The significant unobservable inputs used in IGI’s contingent consideration valuation on December 31, 2025, included: (i) a discount period, based on the expected Milestone payment dates, ranging from 1.7 years to 1.9 years, (ii) a discount rate of 12.3%, and (iii) a management probability estimate of 25% to 50%. The significant unobservable inputs used in IGI’s contingent consideration valuation on December 31, 2024, included: (i) a discount period, based on the expected Milestone payment dates, ranging from 1.7 years to 7.8 years, (ii) a discount rate of 13.2% to 13.5%, and (iii) a management probability estimate of 25% to 50%.
|
|
| Chronix Merger [Member] |
|
|
|
| Business Combination [Line Items] |
|
|
|
| Deferred tax assets related to contingent consideration |
|
$ 0
|
$ 0
|
| Chronix Merger [Member] | Level 3 [Member] |
|
|
|
| Business Combination [Line Items] |
|
|
|
| Payout percentage |
|
10.00%
|
10.00%
|
| Chronix Merger [Member] | Maximum [Member] | Discount rate [Member] | Level 3 [Member] |
|
|
|
| Business Combination [Line Items] |
|
|
|
| Business combination, contingent consideration, liability, measurement input |
|
0.13
|
0.136
|
| Chronix Merger [Member] | Maximum [Member] | Expected term [Member] | Level 3 [Member] |
|
|
|
| Business Combination [Line Items] |
|
|
|
| Business combination, contingent consideration, liability, related patent expiration range term |
|
9 years 8 months 12 days
|
10 years 8 months 12 days
|
| Chronix Merger [Member] | Minimum [Member] | Discount rate [Member] | Level 3 [Member] |
|
|
|
| Business Combination [Line Items] |
|
|
|
| Business combination, contingent consideration, liability, measurement input |
|
0.123
|
0.131
|
| Chronix Merger [Member] | Minimum [Member] | Expected term [Member] | Level 3 [Member] |
|
|
|
| Business Combination [Line Items] |
|
|
|
| Business combination, contingent consideration, liability, related patent expiration range term |
|
8 years 9 months 18 days
|
9 years 9 months 18 days
|
| Chronix Merger [Member] | Valuation Technique, Discounted Cash Flow [Member] |
|
|
|
| Business Combination [Line Items] |
|
|
|
| Unobservable Measurement Input, Uncertainty, Description |
|
The significant unobservable inputs used in Chronix’s contingent consideration valuation on December 31, 2025, included: (i) a discount period, based on the related patent expiration dates, ranging from 8.8 years to 9.7 years, (ii) a discount rate of 12.3% to 13.0%, and (iii) a payout percentage of 10% based on the earnout provision. The significant unobservable inputs used in Chronix’s contingent consideration valuation on December 31, 2024, included: (i) a discount period, based on the related patent expiration dates, ranging from 9.8 years to 10.7 years, (ii) a discount rate of 13.1% to 13.6%, and (iii) a payout percentage of 10% based on the earnout provision.
|
|